Polish-founded Ingenix, a healthcare AI firm developing a pioneering model for simulating clinical trials, secured a seed round.
👯 Founders: Piotr Surma and Adam Dancewicz
📅 Founding year: 2023
🏭 Industry: Biotech
💥 Problem: 90% of pilot drugs fail to gain regulatory approval despite ~$50B annual investment in clinical trials. Drug development is long, costly, and unpredictable.
📣 Solution: Ingenix is developing a proprietary, multimodal and multiscale generative AI co-pilot that simulates clinical trials across molecular to population levels, predicting endpoints and adverse events with high accuracy.
👥 Customers: Pharmaceutical companies and drug development organizations
🌱 Stage: Seed
💰 Investment amount: €9 million
🚀 Funded by: Inovo.vc, OTB Ventures, International Finance Corporation (IFC)
👁️🗨️ Investor’s perspective:
Krzysztof Przybylak, Principal at Inovo.vc: “Ingenix is tackling a research challenge that is both ambitious and complex. At this stage of investment, the only thing that truly matters is the team. Very few teams worldwide are capable of addressing this problem, but after nearly a year of collaboration with Piotr and his team, we had no doubt that Ingenix is one of them—and that we should lead this round.”
💡 It will be spent on: Further development of their proprietary AI platform, team growth, and expanding capabilities to support more complex clinical trial simulations.
💬 In their own words:
“What Adam, myself and the team are developing could have a seismic impact not just on the way clinical trials are conducted, but on the entire sector… The pharmaceutical industry has long been awaiting its ‘GPT moment’.” — Piotr Surma, Co-founder & CEO
💪 Their specialty: Building proprietary, high-performance AI models — proven with the success of Applica, their previous AI company acquired by Snowflake.
🔑 Business model: B2B SaaS / AI-as-a-Service platform for pharmaceutical and biotech companies
👩🏫 Market: Global pharmaceutical R&D market, with a focus on clinical trials and drug development optimization
📊 Traction: Backed by top-tier VCs; strong founding team with exit experience; early validation of deep tech potential
⚡ Competitors: QuantHealth, Unlearn.AI, TrialSpark — but Ingenix differentiates through multiscale simulation capabilities and deep modeling granularity
